Immunizing composition
Inventors
Guss, Bengt • Flock, Jan-Ingmar • Frykberg, Lars • Flock, Margareta
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9987342-B2
Publication Date
2018-06-05
Expiration Date
Abstract
The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.
Core Innovation
The invention provides an antigenic composition comprising polypeptides designated EAG, IdeE, and IdeE2, where the polypeptides are defined by specific SEQ ID numbers and amino-acid intervals. EAG comprises SEQ ID NO: 13, IdeE comprises amino acids 6 to 320 in SEQ ID NO: 30, and IdeE2 comprises amino acids 2 to 345 in SEQ ID NO: 2.
The antigenic composition is used as an immunizing component in a vaccine composition for protecting non-human mammals against infection of Streptococcus equi. The vaccine composition comprises an antigenic composition consisting of the specified polypeptides and a pharmaceutically acceptable carrier, and some embodiments include an adjuvant.
Documented embodiments focus on antigenic and immunogenic epitope determinants derived from Streptococcus equi extracellular proteins, including EAG, IdeE, IdeE2, and related polypeptides such as CNE (SEC), SclC, Eq5, and Eq8. The disclosed work also reports characterization of expressed gene and protein sequences and antigen-antibody-related function, alongside immunization and challenge studies with mucosal and serum IgG readouts and disease outcome assessments.
Claims Coverage
The partial claim set includes two independent claims. One independent claim covers a defined antigenic composition, and the other independent claim covers a vaccine composition for protecting non-human mammals against Streptococcus equi infection using the defined antigenic polypeptides as the immunizing component. Across the two independent claims, the main inventive features are the selected polypeptide set and their use in a vaccine composition with a pharmaceutically acceptable carrier, optionally with adjuvant inclusion.
Defined antigenic composition of EAG, IdeE, and IdeE2
An antigenic composition comprising a polypeptide designated EAG and comprising SEQ ID NO: 13; a polypeptide designated IdeE and comprising amino acids 6 to 320 in SEQ ID NO: 30; and a polypeptide designated IdeE2 and comprising amino acids 2 to 345 in SEQ ID NO: 2.
Vaccine composition for protecting non-human mammals against Streptococcus equi
A vaccine composition for protecting non-human mammals against infection of Streptococcus equi comprising an antigenic composition consisting of a polypeptide designated EAG and comprising SEQ ID NO: 13; a polypeptide designated IdeE and comprising amino acids 6 to 320 in SEQ ID NO: 30; a polypeptide designated IdeE2 and comprising amino acids 2 to 345 in SEQ ID NO: 2; a polypeptide designated CNE (or SEC) comprising SEQ ID NO: 28; a polypeptide designated Eq5 comprising amino acids 2 to 442 in SEQ ID NO: 4; and a polypeptide designated Eq8 comprising amino acids 2 to 197 in SEQ ID NO: 6, as immunizing component; and a pharmaceutically acceptable carrier.
Overall, the independent claims define a precisely specified antigenic polypeptide set and use that set as the immunizing component in a vaccine composition containing a pharmaceutically acceptable carrier for protecting non-human mammals against Streptococcus equi infection.
Stated Advantages
Protecting non-human mammals against infection of Streptococcus equi.
Documented Applications
Immunizing non-human mammals, notably equines, against Streptococcus equi subspecies equi and/or zooepidemicus using multi-component subunit vaccine components including antigenic polypeptides derived from Streptococcus equi extracellular proteins.
Interested in licensing this patent?